A Phase IIa, Open-Label, Randomized Trial in Treatment-naive HIV-1-Infected Subjects to Determine the Antiviral Activity of 14 Days of Monotherapy With 2 Different b.i.d. Dose Regimens of TMC310911 Coadministered With Ritonavir.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TMC 310911 (Primary) ; Ritonavir
Indications HIV-1 infections
Focus Therapeutic Use
Sponsors Janssen R&D Ireland

Most Recent Events

10 Oct 2013 Results published in JAIDS.
30 Apr 2013 TMC310911 had a favorable safety and tolerability profile and demonstrated clinical proof-of-concept, according to a, Ascletis media release.
22 Dec 2012 Planned number of patients changed from 24 to 32 as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight